Macquarie Group’s Compass Therapeutics CMPX Stock Holding History

Macquarie Group’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-340,772	Closed	-$647K	–	1663
2025 Q1	$647K	Buy	+340,772	New	+$906K	﹤0.01%	1446

Other funds holding CMPX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group's CMPX Position: Q2 2025 in Review

Macquarie Group sold out of Compass Therapeutics (CMPX) in Q2 2025, closing a stake of 340,772 shares — an estimated $647K sold.

Macquarie Group first reported a position in CMPX in Q1 2025 and held it in 1 quarter. The position peaked at $647K in Q1 2025. 103 funds tracked by Wall St. Rank hold CMPX as of Q2 2025.

Macquarie Group reported no remaining Compass Therapeutics position as of Q2 2025 after selling out during the quarter.
Macquarie Group sold 340,772 Compass Therapeutics shares in Q2 2025, an estimated $647K.
Macquarie Group first reported a position in Compass Therapeutics in Q1 2025 and held it in 1 quarter.
Macquarie Group's Compass Therapeutics position peaked at $647K in Q1 2025.
103 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2025.

Based on Macquarie Group's 13F filing for Q2 2025, filed 14 Aug 2025.